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The mechanistic and therapeutic differences in the cellular response to DNA-damaging compounds are not completely
understood, despite intense study. To expand our knowledge of DNA damage, we assayed the effects of 12 closely
related DNA-damaging agents on the complete pool of ;4,700 barcoded homozygous deletion strains of
Saccharomyces cerevisiae. In our protocol, deletion strains are pooled together and grown competitively in the
presence of compound. Relative strain sensitivity is determined by hybridization of PCR-amplified barcodes to an
oligonucleotide array carrying the barcode complements. These screens identified genes in well-characterized DNA-
damage-response pathways as well as genes whose role in the DNA-damage response had not been previously
established. High-throughput individual growth analysis was used to independently confirm microarray results. Each
compound produced a unique genome-wide profile. Analysis of these data allowed us to determine the relative
importance of DNA-repair modules for resistance to each of the 12 profiled compounds. Clustering the data for 12
distinct compounds uncovered both known and novel functional interactions that comprise the DNA-damage response
and allowed us to define the genetic determinants required for repair of interstrand cross-links. Further genetic
analysis allowed determination of epistasis for one of these functional groups.
Citation: Lee W, St. Onge RP, Proctor M, Flaherty P, Jordan MI, et al. (2005) Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS
Genet 1(2): e24.
Introduction
Eukaryotic cells possess multiple mechanisms to cope with
structural damage to their DNA. For example, nucleotide
excision repair (NER) excises oligonucleotides containing a
covalently modiﬁed base and resynthesizes the deleted
fragment using the undamaged DNA strand as template [1].
Cell-cycle checkpoints respond to damaged DNA by initiating
a series of phosphorylation and dephosphorylation events
that result in a transient arrest of the cell cycle, providing
time for lesions to be repaired [2,3]. During DNA replication,
multiple pathways ensure the stability and restarting of
stalled replication forks at sites of DNA damage [4,5]. The
sum total of these activities and similar functional repair
‘‘modules’’ are commonly referred to as the DNA-damage
response (DDR).
The study of gene products and pathways that comprise the
DDR has particular relevance to both the etiology and
treatment of cancer in man. A causative role for the DDR
in carcinogenesis is supported by several observations,
including the high degree of genomic instability observed in
tumor cells [6,7] and the number of DDR genes that, when
mutated, lead to cancer or to one of several inherited
disorders characterized by cancer predisposition [8]. Ther-
apeutically, many cytotoxic agents used to treat cancer act by
directly targeting DNA. Therefore, pathways that actively
repair DNA lesions are likely to contribute to the signiﬁcant
problem of clinical drug resistance [9].
The high degree of conservation between the genes and
pathways involved in maintaining genetic integrity in yeast
and all metazoans supports the use of model organisms to
better understand these pathways in man. Indeed, classical
forward genetic screens in Saccharomyces cerevisiae have led to
the identiﬁcation of several genes important for responding
to DNA damage, providing the parts list from which the
current framework of the DDR has emerged [10,11]. The
results of these screens have been augmented by the recent
disruption and barcoding of each predicted yeast open
reading frame which has proven to be a powerful tool in
identifying additional components of the DDR [12–18].
In this study, we used ﬁtness proﬁling [19–22] to inter-
rogate a pooled collection of ;4,700 S. cerevisiae homozygous
deletion strains for sensitivity to 12 agents known to
compromise the structural integrity of DNA (Table 1). Fitness
analysis of individual deletion strains identiﬁed in these
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revealed that the genetic requirements for resistance to
DNA-damaging agents may exceed previous estimates. We
discovered that those strains sensitive to these compounds
carried deletions primarily in genes known to be involved in
DNA metabolism, but we also uncovered genes not previously
known to be related to the DDR. While resistance to a given
compound typically required multiple DDR modules, we
found that the relative importance of these modules was
varied, even when comparing functionally related com-
pounds. The signiﬁcance of our results are 4-fold: (1) we
developed a robust exportable assay to identify and conﬁrm
DDR components; (2) ﬁltering and clustering the data allowed
classiﬁcation of both the mechanism of drug action and gene
function; (3) we used epistasis analysis to identify novel
functional relationships between DDR components; and (4)
we were able to clearly discriminate the genome-wide
response to agents that damage DNA by forming interstrand
cross-links (ICLs) from those that do not.
Results
Fitness Profiling of the Yeast Deletion Collection
The yeast deletion collection is a powerful tool for
identifying genes important for ﬁtness on a genome-wide
scale under a diverse set of environmental conditions
[13,16,20,22–24]. This resource has been particularly valuable
in the study of cellular mechanisms that respond to DNA-
damaging agents [12–14,16,18,25–27]. Each of these studies
has provided new insights into the DDR. The underlying
protocols in these well-executed studies are, however, so
disparate that they preclude any direct comparisons beyond
general conclusions. For example, some studies were per-
formed on solid media, while others used high doses of
compound followed by recovery in liquid media. Further-
more, the data analysis varies from study to study. To provide
a consistent and comprehensive dataset of the DDR, we (1)
proﬁled 12 unique DNA-damaging compounds (six of which
had not previously been proﬁled) (Table 1) using a validated
protocol [22]; (2) conﬁrmed a subset of our microarray ﬁtness
data by individual strain analysis; and (3) where possible,
correlated our results with previously published studies.
Speciﬁcally, we sought to detect mechanistic differences
between compounds that form ICLs (cisplatin, oxaliplatin,
carboplatin, mechlorethamine, mitomycin C, and psoralen)
and those that do not (angelicin, 4-nitroquinoline-1-oxide [4-
NQO], 2-dimethylaminoethyl chloride [2-DMAEC], methyl
methanesulfonate [MMS], streptozotocin, and camptothecin).
In our experiments, ;4,700 homozygous diploid deletion
mutants were grown in pooled cultures in the presence of
compound. Cells were then collected, genomic DNA puriﬁed,
and the unique molecular barcodes present in each strain
ampliﬁed by PCR and hybridized to an oligonucleotide array
carrying the barcode complements. The relative ﬁtness of
each strain was then determined by comparing the signal
intensity for each strain on the microarray to the corre-
sponding intensities obtained from a series of no-drug
control arrays (see Materials and Methods; Dataset S1;
Protocol S1).
Validating the Approach by Individual Strain Confirmation
Little experimental evidence directly addresses how well
ﬁtness defects or sensitivities measured by microarray
analysis correlate with actual growth rates of individually
cultured strains. To directly address this issue, we cultured
the 233 deletion strains most sensitive to mechlorethamine
individually (as determined from three replicate microarray
experiments, see Materials and Methods). The individual
growth rates of these strains were measured, both in the
presence and absence of mechlorethamine, by taking optical-
density readings of liquid cultures every 15 min for 30 h
(Dataset S2; Protocol S2). Figure 1A shows representative
growth curves for 32 of these cultures (16 in dimethyl
sulfoxide [DMSO, diluent control] and 16 in mechloreth-
amine). We deﬁned the sensitivity to mechlorethamine of
each strain by calculating the difference between the average
doubling time (AvgG) in DMSO and in mechlorethamine (see
Materials and Methods). These values were then normalized
to wild-type and plotted against their corresponding ﬁtness-
defect scores as measured from the microarray (Figure 1B).
We observed a highly signiﬁcant correlation (R
2¼0.5086, p¼
8.5e 38; data not shown). When we removed strains exhibit-
Table 1. Summary of Compounds, with References Indicated
Compound ICL Mono-
adduct
Methyl-
ation
Alkyl-
ation
Clinically
Used
Genome-
Wide
Screen
Cisplatin [79] [37] [79] [18,22]
Carboplatin [79] [37] [79]
Oxaliplatin [79] [37] [79] [18]
Mitomycin C [79 [37] [79] [79] [18]
2-DMAEC [41,80] [41,80]
Mechlorethamine [79] [79] [79] [79]
Angelicin [81]
Psoralen [37] [37] [79] [79]
Streptozotocin [82] [83] [83] [79]
MMS [12] [12] [12] [12]
4-NQO [84]
Camptothecin [79] [17]
DOI: 10.1371/journal.pgen.0010024.t001
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Synopsis
Cells have evolved sophisticated ways to respond to DNA damage.
This is critical because unrepaired damage can kill cells or cause
them to become cancerous. The response to DNA damage has been
studied for more than 50 years, and has been found to be extremely
complex. The traditional way of understanding this complexity is to
divide the process into its component parts with the goal of
eventually reconstituting the entire process. In this study, the
authors extend classical approaches using genomics—an approach
that involves studying all genes in an organism simultaneously. The
authors tested 12 distinct compounds (many used in cancer
chemotherapy) that damage DNA and uncovered new genes
involved in DNA repair. They then grouped the compounds to
define how they attack cells. Using this approach, the study found
that many similar DNA-damaging agents act in comparable ways to
damage DNA, but surprisingly, similar compounds can also act on
cells by very different mechanisms. Specifically grouping the
findings together and verifying the significant results lends a high
degree of confidence in the data. The development of such a
reproducible experimental design is important for inspiring future
experiments.ing ﬁtness defects in the absence of drug from the analysis,
this correlation increased (R
2 ¼ 0.7462; p ¼ 5.4e 57). This is
consistent with slow-growing strains yielding artiﬁcially low
ﬁtness-defect scores in microarray-based ﬁtness analysis of
pooled cultures (see Overall Experimental Design). Of 233
individual strains analyzed, 206 exhibited signiﬁcant mech-
lorethamine-dependent ﬁtness defects compared to that of a
wild-type strain (see Materials and Methods).
To further test how well our signiﬁcance calling in our
microarray experiments correlated with individual growth
rates, we compared a calculated false-discovery rate (FDR)
[28,29] with a measured FDR for the top 81 most sensitive
strains according to the combined results for pooled growth
in mechlorethamine (Table 2). The FDR calculation allows us
to establish a ﬁtness-defect score threshold for a given
acceptable rate of false discovery. Speciﬁcally, we calculated
the cut-off for several FDRs and examined the individual
growth curves of strains that were designated as signiﬁcant at
these cut-offs. For example, the array results show that a 5%
FDR cut-off results in 37 sensitive strains from the pooled
experiments. The individual growth curves of these 37 strains
reveal that 35 of them are indeed sensitive to mechloreth-
amine, giving us a 5.4% FDR (two out of 37). For this drug,
our measured FDR is lower than the calculated FDR. It should
be noted that although the above underscores the low FDR in
our experiments, it can not address the extent of the false-
negative rate.
Overall Experimental Design
As we reﬁned our assay for the DNA-damaging agents, it
became apparent that the length of time for which cells are
exposed to compound has a dramatic effect on the sensitivity
of deletion strains lacking those genes most required for
growth. Speciﬁcally, in our standard assay design, frozen
aliquots of the deletion collection are recovered in rich
media for ten generations until they reach logarithmic
growth phase [22]. Compound is then added and the culture
is robotically grown for precisely 20 generations. This
prolonged chronic exposure allows for detection of those
gene products that are required for resistance even for those
gene products that have small (,5%) growth defects. We used
this standard assay to proﬁle four compounds: mechloreth-
amine, cisplatin, streptozotocin, and camptothecin. The
results of these experiments made it clear that any deletion
strain exhibiting a slow-growth phenotype in the absence of
compound becomes depleted from the pool even before the
Figure 1. Comparison of Individual Strain Analysis to Microarray Results
(A) Representative growth curves of 16 individual strains grown in the presence of solvent alone (DMSO, red curve) and 62.5 lM mechlorethamine
(black curve). Growth was monitored by measuring the optical density (OD600) of cultures every 15 min for 30 h. The fitness of each strain was defined
by the difference between the average doubling times in mechlorethamine and in DMSO (see Materials and Methods).
(B) Correlation between growth rates of individual strains and microarray-based fitness estimates. The ratio of growth rates of the 186 individual
homozygous deletion strains (the top 233 ranked mechlorethamine-sensitive strains as determined by three replicate microarray experiments minus 47
strains which exhibited a slow-growth phenotype when individually cultured in the absence of mechlorethamine) over an average wild-type growth
rate are plotted on the x-axis against the average fitness-defect scores from three pool experiments on the y-axis. The correlation (R
2¼0.7462) is highly
significant (p ¼ 5.4e 57).
DOI: 10.1371/journal.pgen.0010024.g001
Table 2. Calculated FDR Versus Experimentally Measured FDR
Calculated
FDR
Threshold
Rank in Pool
Experiments
Confirmed
Individual
Growth Defect
Measured
FDR
0.001 1–17 17/17 0.000
0.05 1–37 35/37 0.054
0.30 1–81 78/81 0.037
DOI: 10.1371/journal.pgen.0010024.t002
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Genome-Wide Response to DNA Damagecompound is applied. As a consequence, this experimental
design precludes any meaningful measure of the ﬁtness of this
subset of strains. To circumvent this problem, we altered our
experimental protocol in the following way: frozen pool
aliquots were thawed and immediately exposed to compound
for the equivalent of ﬁve generations of wild-type growth.
Control experiments showed no non-speciﬁc sensitivity of
the wild-type strain as a result of cells recovering from a
frozen state using this protocol (data not shown). This revised
experimental design was used to screen the 12 compounds
(see Table 1) because (1) this low number of generations
minimizes the false-negative rate resulting from slow-growing
strains; and (2) these experiments should identify gene
products immediately required for resistance to compound.
The advantages of this design are demonstrated by examining
the rad51D and rad52D homozygous deletion strains, both of
which are defective for homologous recombination-mediated
repair [30]. Both are acutely sensitive to mechlorethamine but
also exhibit a slow-growth phenotype in the absence of
mechlorethamine (see Figure 1A). In the standard 20-
generation assay, however, the ﬁtness-defect scores of these
deletion strains in mechlorethamine ranked 1,676 and 2,051,
respectively, among the other ;4,700 strains in the pool
(where the strain most sensitive to mechlorethamine has a
rank of 1). When the revised experimental design was used,
the average rank of these strains increased to 21 and 23,
respectively. Therefore, in the former case, neither strain was
sensitive, but in the latter case, both were extremely sensitive.
Despite our observation that the shorter-generation assay
detected many DDR genes, comparing the ﬁve-generation
assay with the standard 20-generation assay yielded addi-
tional insight. For example, there is an increase in strains that
are deleted for genes classiﬁed as ‘‘other’’ or ‘‘unknown’’ that
exhibit ﬁtness defects only after extended exposure (i.e. 20
generations) to compound (Figure 2A). Particularly interest-
ing examples are strains defective in DNA-damage check-
points. Table 3 summarizes the average rank of ﬁve
checkpoint-defective strains (rad9D, rad24D, rad17D, ddc1D,
and mec3D) following ﬁve or 20 generations of pool growth in
500 lM cisplatin. We followed up on this result by monitoring
the growth rate of these individual strains during the ﬁrst ﬁve
and second ﬁve generations of growth in cisplatin (Figure 2B).
Strikingly, both the rad9D and rad24D strains exhibited
accelerated growth relative to wild-type during the ﬁrst ﬁve
generations, consistent with a lack of checkpoint-mediated
cell-cycle arrest [31,32]. Despite this accelerated growth, these
strains exhibited reduced viability even at the ﬁve-generation
point (Figure 2C). Consistent with this observation during the
next ﬁve generations (6–10), these mutants did exhibit a
reduced rate of growth, presumably due to the accumulation
of DNA and chromosomal damage associated with uncon-
trolled progression through the cell cycle. Notably, the
growth rate of deletion strains rad17D, ddc1D, and mec3D,
whose protein products form a complex loaded onto DNA at
sites of damage in a RAD24-dependent manner [33], were
indistinguishable from that of a rad24D strain (Figure 2C; data
not shown). These results may explain the discrepancy
between conﬂicting reports that address the requirement of
checkpoint genes for resistance to cisplatin [18,34,35].
In addition to checkpoint-defective strains, a number of
other deletion strains exhibited sensitivity only after 20
generations of growth. These strains, however, do not exhibit
accelerated growth at ﬁve generations but appear to be
required only after long-term chronic exposure. These strains
are deleted for genes that modify chromatin structure and
are involved in the respiratory chain (Table S1). Despite the
lack of an observable growth defect at ﬁve generations, we
hypothesized that some of these strains, depending on the
cause of their sensitivity, may have reduced viability. To test
this, we plated serial dilutions of individual strains (that
exhibited sensitivity after 20 generations, but not after ﬁve
generations) on yeast extract/peptone/dextrose (YPD) follow-
ing ﬁve generations of growth in 500 lM cisplatin (Figure 2C).
Of the four we tested, gcs1D, swi4D, rtf1D, and yme1D, none
showed an increased loss of viability. Liquid cultures of these
strains conﬁrmed these results, as a decrease in growth rate
compared to wild-type is only observed at later-generation
time points, and is not observed at the ﬁve-generation time
point.
Interstrand DNA Cross-Linkers
In this study, we examined the effects of a variety of DNA-
damaging agents, but placed particular emphasis on com-
pounds that induce cross-links between complementary
strands of DNA (the ICLs). Even though each of the six ICL-
inducing compounds we proﬁled cause a variety of structural
damage to DNA (see Table 1), the cytotoxic effects of these
compounds are attributed primarily to ICLs [36]. These
compounds differ in the efﬁcacy with which they induce ICLs,
ranging from 30–40% of all lesions for psoralen to 1–5% of
all lesions for mechlorethamine [37]. They also differ in their
preferred substrates. Mitomycin C, for example, typically
cross-links guanines at CpG sequences [38], whereas psoralen
predominantly cross-links thymines at TpA sequences [39].
Previous studies have suggested that ICL tolerance in yeast
can be attributed to three major pathways: NER, homologous
recombination repair (HRR), and post-replication repair
(PRR) [18,35,40]. Our results corroborate these ﬁndings as
strains carrying deletions in genes of the NER (RAD2, RAD4,
RAD10, RAD1, and RAD14), HRR (RAD57, RAD55, RAD51,
RAD52, RAD54, and RAD59), and PRR (RAD6, RAD18, and
RAD5) pathways were found to be highly sensitive to each of
the six ICL-inducing compounds we tested. Figure 3 depicts
the relative requirement for each of several DNA-repair
modules. Although the genes that make up these modules are
somewhat arbitrarily assigned, we believe that they are
generally acceptable in the DNA-damage community and,
moreover, provide a simple visual depiction of some of the
important differences between compounds. Figure 3 provides
only an overview (for more detail, see Supporting Informa-
tion). Examining the top 30 sensitive strains for a given
compound and the relative sensitivity rankings for these
strains gives a snapshot of the ﬁrst line of defense against the
damage induced by that compound. The gene groups with the
lowest ranks contain genes that, when deleted, result in the
greatest sensitivity to that drug and therefore are presumably
most important in conferring resistance. Extending this list to
the top 250 sensitive strains then begins to show a more
general view of other DDR pathways that are also involved in
responding to damage caused by that agent.
The genes from these pathways are also important for
resistance to additional types of DNA damage, as is evidenced
by the proﬁles of other compounds (Figure 3). Therefore,
their sensitivity to cross-linking agents could be due to a
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Genome-Wide Response to DNA Damagecombined deﬁciency in the repair of ICLs as well as other
DNA lesions. To identify strains whose sensitivity was entirely
due to a lack of ICL repair, we screened the compounds
angelicin and 2-DMAEC, monofunctional analogues of
psoralen and mechlorethamine, respectively. The most
striking difference between these proﬁles was the relative
sensitivity of the pso2D deletion strain, which ranked among
the most sensitive strains in psoralen and mechlorethamine
(and indeed all other cross-linking compounds), but which
exhibited no detectable sensitivity to angelicin or 2-DMAEC.
These observations are consistent with previous ﬁndings for
PSO2 [41], whose protein product is thought to facilitate the
repair of ICLs as a part of the NER pathway [40]. Further
comparisons between ICL and non-ICL-inducing compounds
underscored the importance of translesion DNA synthesis
(TLS) to the repair of ICLs. This is consistent with previous
ﬁndings for REV1, REV3, and REV7, which operate in a
branch of PRR [42,43]. Unlike PSO2, however, the role of
these genes in the DDR is unlikely to be restricted to ICL
repair [44].
Of the six ICL-inducing compounds, carboplatin and
mitomycin C resistance required a signiﬁcantly larger
number of genes whose biological function was not pre-
viously linked to DNA metabolism. Generally speaking,
however, with respect to well-characterized DNA-damage-
responsive pathways, there was a high level of correlation
between the genetic requirements for resistance among the
ICL-inducing compounds that we proﬁled. There were,
however, some exceptions to this. Genes encoding the MRX
complex (MRE11, RAD50, and XRS2), involved in the repair
of DNA double-strand breaks [45], were particularly impor-
tant for resistance to mechlorethamine (see Supporting
Information). Strains deleted for the genes MUS81 and
MMS4, whose protein products are thought to form a
structure-speciﬁc endonuclease important for restarting
stalled replication forks [46,47], were highly sensitive to each
cross-linker with the exception of psoralen. Finally, resistance
to carboplatin appeared less dependent on NER machinery
when compared to other cross-linkers, including other
members of the platinum family. This is surprising because
the mechanism of action and the spectrum of clinical activity
of cisplatin and carboplatin are more similar to each other
than to oxaliplatin [48].
Non-Cross-Linking DNA-Damaging Agents
We also proﬁled ﬁve compounds that covalently modify
DNA but do not induce ICLs. These included the aforemen-
tioned angelicin and 2-DMAEC, as well as streptozotocin,
Table 3. Comparison of the Average Ranked Sensitivity of Five
DNA-Damage-Checkpoint Mutants from Experiments in which
the Pooled Homozygous Deletion Collection Was Exposed to
500 lM Cisplatin for Either Five or 20 Generations
Strain Rank (5 g) Rank (20 g)
rad9D 4,482 42
mec3D 2,542 37
ddc1D 3,775 389
rad17D 4,197 316
rad24D 4,426 192
DOI: 10.1371/journal.pgen.0010024.t003
Figure 2. The Effect of Exposure Duration on the Genetic Requirements for Resistance to DNA-Damaging Agents
(A) Pie charts showing relative percentage of sensitive genes categorized into either ‘‘DNA metabolism’’, ‘‘unknown’’,o r‘‘other’’. All of the Gene
Ontology [63] slim annotations (ftp://ftp.yeastgenome.org/yeast/data_download/literature_curation/go_slim_mapping.tab. Accessed February 17,
2005) are combined into ‘‘other’’ except for those classified in the unknown or DNA-metabolism category. The relative distributions of the
mechlorethamine experiments are shown as a function of both time and gene rank.
(B) BY4743 (wild-type) and the DNA-damage-checkpoint mutants, rad9D and rad24D, were grown in the presence of 500 lM cisplatin over the course of
ten population doublings. Yeast cultures were maintained in an exponential phase of growth by robotic dilution of cultures after five doublings into
fresh media containing cisplatin. The growth of each deletion strain (black curve) is compared to that of BY4743 (red curve) between 0–5 (left) and 6–10
(right) population doublings. The rad9D and rad24D deletion strains exhibit accelerated grow rates in the first five generations, but by ten generations
begin to demonstrate slow growth as compared to wild-type.
(C) Viability assay of strains treated with cisplatin or DMSO for five generations. Indicated strains were removed from cultures after they reached an
OD600 of 2.0, and were diluted as shown. Strains were chosen based on the criteria that they did not show a growth defect at five generations but did
show a growth defect at 20 generations. Dilutions were pinned onto YPD plates in a 5-fold concentration series. The wild-type parental diploid strain is
compared to several diploid deletion strains that exhibited a decrease in viability: ddc1D, rad24D, rad17D, mec3D, and rad9D. In contrast, several of
these strains showed little or no decrease in viability at five generations of growth: swi4D, yme1D, rtf1D, and gcs1D. This figure underscores the point
that, despite the lack of an apparent growth defect in liquid culture, several deletion strains lose viability relatively rapidly when exposed to cisplatin.
DOI: 10.1371/journal.pgen.0010024.g002
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Genome-Wide Response to DNA DamageMMS, and 4-NQO. Streptozotocin and MMS are both
clinically used cytotoxics that methylate DNA primarily at
the N-7 position of guanine residues. They also generate,
albeit at a lower frequency, the more toxic O-6 methylgua-
nine and N-3 methyladenine adducts [49,50]. 4-NQO reacts
with DNA to form several high-molecular-weight adducts
including 3-(deoxyguanosine-N2-yl)-4-aminoquinoline-1-ox-
ide, N-(deoxyguanosine-C8-yl)-4-aminoquinoline-1-oxide,
and 3-(deoxyadenosine-N6-yl)-4-aminoquinoline-1-oxide
[51].
The ﬁtness proﬁles of these ﬁve DNA-modifying com-
pounds were similar in so far as strains deﬁcient in HRR,
PRR, and MUS81/MMS4 exhibited sensitivity to all ﬁve
compounds (Figure 3). This likely reﬂects a common ability
of these compounds to cause lesions that impede the
advancement of DNA-replication forks during S-phase. There
were also several differences in the ﬁve ﬁtness proﬁles. To
remove DNA adducts, the cell can employ one of several
excision-repair mechanisms, the selection of which is based
on the size of the offending DNA adduct [52]. In agreement
with this, we found that NER was important for resistance to
compounds that cause bulkier DNA adducts (angelicin and 4-
NQO), whereas MAG1, encoding a DNA glycosylase of base
excision repair [53,54], was important for resistance to the
methylating activities of streptozotocin and MMS. Interest-
ingly, MAG1 appeared to be more important for resistance to
MMS than to streptozotocin, based on rank.
A sixth non-cross-linking agent proﬁled, camptothecin, is
distinct from the other compounds in this study because it
inhibits the activity of an enzyme rather than directly
modifying DNA. Camptothecin inhibits the enzyme top-
oisomerase I (Top I), and stabilizes a covalent enzyme–DNA
intermediate [55]. During replication, collision of the
replication machinery with this protein–DNA complex causes
double-strand breaks. Our assay revealed a unique sensitivity
proﬁle for camptothecin. Strains deﬁcient in the MUS81/
MMS4 complex and HRR showed the greatest sensitivity to
camptothecin, as expected for a treatment that induces
stalled replication forks. Neither PRR nor excision-repair
mechanisms appeared to play a prominent role in conferring
resistance to camptothecin.
Uncharacterized Genes
Of the 36 array experiments examined in this study, 283
strains scored signiﬁcantly sensitive in at least one experi-
ment when a 5% FDR threshold was used. Among these 283
strains, 87 are sensitive in three or more independent
experiments and four of these strains contain deletions in
unnamed genes (Table S2). The most notable of these four
strains is YDR291W, a gene encoding a putative DNA helicase
that appears to be involved in repairing mechlorethamine-
induced lesions. The amino acid sequence of Ydr291w is
conserved across many organisms, including mammals
(BLASTP E-value ¼ 3.0e 08 to Human RecQ4 [56]), and its
proposed helicase function is due to its helicase sequence
motifs [57]; the function of this yeast open reading frame is
currently being tested. Ymr073c is also conserved from yeast
to man (BLASTP E-value ¼ 7.0e 09 to a human cytochrome
oxidoreductase), and our results suggest it is involved in
resistance to carboplatin and cisplatin. The ylr426wD deletion
strain showed sensitivity in mechlorethamine and streptozo-
tocin, and its protein product is similar to a human peptide
annotated as a dehydrogenase (BLASTP E-value ¼ 6.0e 05).
The YKL075C mutant strain was sensitive in both streptozo-
tocin and camptothecin at 20 generations of exposure, and is
only conserved with another fungus, Ashbya gossypii. All four of
these unnamed genes have detectable protein expression in S.
cerevisiae (.50 molecules/cell) [58,59].
The paucity of unnamed genes in our results is likely due to
the stringency of the signiﬁcance cut-off we used to minimize
false positives as well as being a consequence of the level of
attention that DNA-repair pathways have received. An
equally important factor is the ﬁnding that many of the
named genes do not properly reﬂect the complexity of their
cellular roles. Speciﬁcally, many of the sensitive strains that
Figure 3. The Relative Importance of Well-Characterized DDR Modules
for Resistance to Different DNA-Damaging Agents
Detailed examination of strains with mutations in DNA-damage-response
genes. Each bar graph represents only strains that were found to be
among the top 30 (or 250) most sensitive strains in that compound and
are known to be members of a well-characterized DNA-damage-
response pathway. The bars represent the median rank for genes in
each of the gene groups listed in the visual key. The gene groups were
defined in the following way: x-linking genes (PSO2); NER (RAD2, RAD4,
RAD10, RAD1, and RAD14); PRR (RAD6, RAD18, and RAD5); error-prone TLS
(REV1, REV3, and REV7); HRR (RAD57, RAD55, RAD51, RAD52, RAD54, and
RAD59); stalled replication-fork repair (MUS81 and MMS4). Those
compounds that form ICLs are labeled with an asterisk.
DOI: 10.1371/journal.pgen.0010024.g003
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importantly, their roles in the DDR are largely unknown. For
example, the RMD7 mutant appears sensitive to several cross-
linking compounds yet is named for being required for
meiotic division [60]. Other genes are better characterized,
but thus far are only known to have functions not involved in
the DDR (e.g., RTT101 [regulates Ty1 transposition, though
other RTT genes are DDR genes, such as ELG1, MMS1, and
RTT107], and LTE1 [essential for growth in low temper-
atures]) [61,62]. Overall, the 283 strains making the sensitivity
cut-off in at least one experiment contain 34 strains deleted
for genes with no functional annotation (by Gene Ontology
[63]), and roughly half are annotated in processes unrelated
to DNA repair (Table S2). Our results provide functional data
that these genes are in fact involved in the DDR and suggest
additional experiments to further characterize them.
Global Analysis
To analyze the 36 array experiments presented here in a
global manner, we applied hierarchical clustering techniques
to the ﬁtness-defect scores (Figure 4A). The dataset used for
clustering was restricted to strains designated as signiﬁcant
(5% FDR) in two or more of the array experiments, and thus
represented only the most highly sensitive strains identiﬁed
in this study. This produced a matrix of ﬁtness-defect scores
(141 strains336 experiments). An examination of the clusters
across the experiment axis showed that, as expected,
compounds predicted to have similar mechanisms of action
group together, lending conﬁdence in the robustness of the
analysis. Members of the platinum family of compounds are
highly correlated, as are MMS and streptozotocin, the only
two agents proﬁled that possess DNA-methylating activity.
The genome-wide data was highly reproducible, evidenced by
the fact that all replicates correlate as nearest neighbors.
When the clustered results are viewed along the gene axis,
we predicted there would be a high correlation in ﬁtness
proﬁles between strains with deﬁciencies in genes in the same
DNA-repair pathway (Figure 4B), and this prediction was
conﬁrmed. This result holds true for several DNA-repair
epistasis groups, including NER, PRR, HRR, error-prone TLS,
and cell-cycle checkpoint control (see Figure 4A).
The clustering analysis suggested additional novel func-
tional interactions. We focused on one particular cluster
within the dataset that included ﬁve genes: MPH1, SHU1,
SHU2, CSM2, and PSY3. The latter four genes encode proteins
that physically interact with one another and belong to a
single epistasis group that appears to operate in a branch of
HRR [64,65]. MPH1 was also shown to be epistatic with
members of the HRR pathway [66], and the Mph1 protein, as
predicted by its amino acid sequence, was recently shown to
possess DNA helicase activity [67]. To our knowledge,
however, no direct functional link between MPH1 and the
other four genes has been reported. To test whether such a
link exists, as suggested by our clustering analysis, we
generated double mutants between MPH1 and each of the
other four genes and measured the sensitivity of these strains
to MMS. We found that single and double deletion strains
exhibited similar sensitivity to MMS, indicating that MPH1 is
epistatic with SHU1, SHU2, CSM2, and PSY3 (Figure 4C).
Conversely, the addition of an MPH1 deletion to strains
carrying deletions known to compromise other deﬁned DNA-
damage pathways, such as MUS81 (stalled replication-fork
repair) and MAG1 (base excision repair), exacerbated the
sensitivity to MMS (Figure 4C).
Discussion
The high level of scrutiny paid to the DDR in yeast and
other model organisms has yielded a wealth of data. In this
study, we set out to address two aims. First, we sought to
collect a sufﬁcient number of ﬁtness-proﬁle signatures for
compounds with similar mechanisms of action. This would
allow us to test whether we could identify differences in
compound proﬁles that might provide correlative insight into
their diverse clinical efﬁcacy. Second, we aimed to develop a
standard assay platform, including all protocols and strains so
that they can be exported to any laboratory. We believe that
such a standard set of protocols will provide a powerful
resource to the entire community and will allow for the
development of a centralized database for the exchange of
information.
While classical forward genetic screens in yeast have been
instrumental in identifying important components of the
DDR, it is unlikely that saturation across the genome has been
achieved. In contrast to traditional genetic analysis, the
approach employed here enabled the systematic interro-
gation of the comprehensive set of all 4,758 homozygous
deletion strains, representing nearly all non-essential genes in
the yeast genome. Furthermore, because the ﬁtness-defect
scores obtained with this method display a continuous range
of sensitivity and these sensitivities correlate well with
independently measured growth rates (see Figure 1B), genes
can be ranked according to their relative importance in
conferring resistance to a given compound. This provides a
high level of resolution and allows distinctions to be made
between functionally related compounds, even in cases where
the genetic elements required for ﬁtness largely overlap. For
example, cisplatin, oxaliplatin, and carboplatin are structur-
ally related chemotherapeutic drugs and, for each, their
cytotoxicity is attributed primarily to their ability to induce
ICLs. Predictably, ﬁtness proﬁling of each compound
identiﬁed the major pathways important for resistance to
DNA cross-linking agents (PSO2/NER, HRR, and PRR). The
ﬁtness proﬁle for carboplatin, however, was unique among
the platinum-based compounds in that PRR was found to
hold far greater importance in conferring resistance than the
other pathways (see Figure 3). Carboplatin’s distinctive
proﬁle is also apparent upon hierarchical clustering of the
data (see Figure 4A), and could potentially reﬂect differences
in the spectrum of structural damage to DNA or in cell-cycle-
speciﬁc reactivity of the drug.
Although DNA-targeting drugs are typically viewed as non-
speciﬁc, the cellular response to both diverse and functionally
similar DNA-damaging agents is clearly distinct as is
evidenced by their speciﬁc clinical applications [68]. It is
important to note that most of these agents were used before
their mechanism of action had been deﬁned, and their
effectiveness is still deﬁned empirically. Given this fact and
the fact that DNA will remain an excellent therapeutic
oncology target, particularly as more selective and less toxic
compounds are developed, high-throughput assays capable of
deﬁning drug action will undoubtedly prove useful. In this
study, we used 12 compound proﬁles (Table 1) to deﬁne a
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DNA-damaging compounds can be compared.
Because the measured sensitivity of each strain in a given
proﬁle is a continuum of sensitivity as measured by growth
inhibition, it is difﬁcult to gauge the point at which ﬁtness-
defect scores cease to reﬂect signiﬁcant defects in growth. We
therefore sought to conﬁrm the sensitivity detected in
competitive pools by growing individual strains þ/  the
compound mechlorethamine. We found that 88% of the
233 strains most sensitive to mechlorethamine (based on
rank) were also found to be sensitive in our individual growth
assay (see Table 2). Thus, our assay has the advantage of
having a measurable FDR that appears much lower than our
calculated FDR [69]. This result is signiﬁcant on several levels.
First, we found 34 uncharacterized genes suggesting, as
predicted, that our understanding of the DDR is still
incomplete. Second, these results suggest that by choosing a
stringent signiﬁcance cut-off, we have likely missed other
DDR genes, and the raw data from these screens should
provide a rich data source for further analysis. Added to this
complexity is our observation that several strains exhibit
compound sensitivity only following extended drug exposure.
By conducting our assay for both ﬁve and 20 generations of
growth, we have gleaned a more comprehensive representa-
tion of the DDR. This enabled us to establish deﬁnitively a
role for ﬁve checkpoint genes in conferring resistance to
cisplatin (see Figure 2)—an observation for which there has
been no consensus in the literature.
Our assay is distinct from expression studies, where an
equivalent conﬁrmation assay would represent hundreds of
Northern blots or quantitative PCR assays to verify expres-
sion changes. In addition, expression arrays do not allow a
ranking of genes as it is not clear how or if the magnitude of
expression change is biologically signiﬁcant. The fact that our
assay allows a ranking of sensitivities, and conﬁrmation of this
ranking, makes it distinct from several colony-based studies
using the yeast deletion collection. These solid-media assays
for sensitivity are not highly quantitative, though spot-
dilution conﬁrmation does allow some measure of relative
sensitivities.
In summary, despite signiﬁcant advances in the breadth
and depth of our understanding of the DDR, additional cell-
based analyses are required before we can claim to fully
understand DNA replication, recombination, and repair [70].
We believe that a new theme has emerged in these studies,
however, in that the combined use of chemicals with genetic
deletions can deﬁne functional groups that, in the absence of
compound, would not be uncovered. For example, hierar-
chical clustering of the most highly sensitive strains identiﬁed
using a combination of chemical and genetic perturbations
successfully predicted novel epistatic interactions between
the MPH1 gene and SHU1, SHU2, CSM2, and PSY3. Even
though they comprise a major defense mechanism against
several DNA-damaging agents, a role for these ﬁve gene
products in a branch of HRR is only now beginning to emerge
[65,66]. Further analysis of this dataset will undoubtedly
uncover additional functional relationships whose discovery
has thus far remained elusive. Finally, increased use (and
increased availability) of chemical inhibitors to probe the
yeast deletion collection should provide a more comprehen-
sive, contextual understanding of cellular physiology.
Materials and Methods
Reagents. Cisplatin, carboplatin, oxaliplatin, psoralen, angelicin,
streptozotocin, 2-DMAEC, mechlorethamine, MMS, camptothecin,
and 4-NQO were purchased from Sigma-Aldrich (St. Louis, Missouri,
United States). Mitomycin C was purchased from Calbiochem (San
Diego, California, United States). Each of these compounds was
dissolved in DMSO, aliquoted, and stored at 20 8C until use, with the
exception of cisplatin, which was used immediately following
resuspension, and carboplatin, oxaliplatin, and 2-DMAEC, which
were dissolved directly in YPD media at the time of the experiment.
Strains and media. Yeast was maintained in YPD media [71,72] at
30 8C unless stated otherwise. Strains used for individual analysis in
this study are listed in Table S3 and were obtained from the yeast
deletion collection or constructed de novo using PCR-based gene
replacement [73]. Using this method, the nat or hph genes, conferring
resistance to the antibiotics nourseothricin or hygromycin B,
respectively [74], were PCR-ampliﬁed from plasmids and transformed
into the appropriate background strain using a modiﬁed LiOAc-
based protocol [75,76]. Transformants were selected on YPD
containing antibiotic (100 lg/ml nourseothricin or 300 lg/ml
hygromycin B), and successful gene-replacement events were veriﬁed
by PCR.
Deletion-pool construction and growth. The homozygous deletion
pool was constructed as described [22] and stored in 20-ll aliquots at
 80 8C. For the ﬁve-generation experiments, aliquots of the pool were
thawed and diluted in YPD to an optical density at 600 nm (OD600)o f
0.0625 and a ﬁnal volume of 700 ll. Compound was then added and
the pool was grown for ﬁve generations in a Tecan GENios
microplate reader (Tecan, Durham, North Carolina, United States).
For the 20-generation experiments, the thawed pool was ﬁrst
recovered for ten generations of logarithmic growth, diluted as
above, and grown in the presence of compound over 20 generations.
Cells were maintained in logarithmic phase by robotically diluting
cultures every ﬁve doublings using a Packard Multiprobe II four-
probe liquid-handling system (PerkinElmer, Wellesley, California,
United States) [23].
Experiments involving the two UVA light-activated compounds
(psoralen and angelicin) were performed as described above with the
following modiﬁcations: the pool was diluted to OD600 of 0.625 and
compound was added to 70 ll of this cell suspension, which was then
exposed to UVA light via a handheld UVA lamp (Ambion, Austin,
Texas, United States) for 15 min. Following irradiation, cells were
Figure 4. Hierarchical Clustering of Genome-Wide Profiles Identifies Mechanistic Relationships Between Drugs and Functional Relationships Between
Genes
(A) Clustergram containing all strains significant in two or more array experiments. Raw fitness-defect values were hierarchically clustered using
Spearman’s rank correlation. Colored bars represent gene clusters of note, including NER (RAD2, RAD4, RAD10, RAD14, and RAD1—blue); error-prone TLS
(REV1 and REV3—red); PRR (RAD6, RAD18, and RAD5—yellow); homologous recombination (RAD57, RAD51, and RAD54—green); cell-cycle checkpoint
control (RAD9, RAD24, RAD17, DDC1, and MEC3—orange); and a cluster shown in (B) (SHU2, SHU1, CSM2, MPH1, and PSY3—magenta).
(B) Zoom view showing one cluster containing the class I NER genes and a second cluster containing several uncharacterized DNA-repair genes. Four of
these five genes (SHU1, SHU2, CSM2, and PSY3) are known to encode proteins that physically interact [65,77,78].
(C) Individual growth curves of single and double deletion strains with MPH1 in 0.002% MMS. In all panels, the growth of wild-type (BY4741) is
represented by the black curve and the growth of mph1D by the red curve. The growth of eight different deletion strains (shu1D, shu2D, csm2D, psy3D,
mag1D, mus81D, rad51D, and rad54D) are shown in green, and double mutants, in which the MPH1 deletion is added to each of the above, are shown in
blue. Double mutants of MPH1, MAG1, and MUS81 show additive or synergistic sensitivity to MMS, whereas double mutants of MPH1, with the four
other genes in its cluster, show no additional sensitivity to MMS, suggesting that MPH1 is epistatic with SHU1, SHU2, CSM2, and PSY3.
DOI: 10.1371/journal.pgen.0010024.g004
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described above.
Genomic DNA preparation, PCR, and microarray hybridization.
Genomic DNA preparation, PCR ampliﬁcation of molecular tags, and
microarray hybridization were as described (Datasets S3 and S4;
Protocol S3) [23].
Data analysis. Fitness-defect scores were calculated for each strain
in the pool for each experiment. These scores are based on a tag-
speciﬁc algorithm that takes into account the intensities of each tag
on the experimental array and the corresponding intensities on a set
of control arrays performed on the pool without compound (the
control set). The majority of strains carry four tags that hybridize to
the array: upstream tag (uptag), uptag antisense, downstream tag
(dntag), and dntag antisense. The tag intensities are log transformed,
mean normalized, and the intensities of the two strands of each tag
are averaged into a single value for each tag. Next, a mean and
standard deviation are calculated for the uptag and dntag intensities
for each strain across the set of control arrays. A z-score for upstream
and downstream tags for each strain is then calculated by taking the
difference of the average intensities between the control and
treatment and dividing by the standard deviation of the control-set
intensities. The result is two z-score values for the upstream and
downstream tags; these are then averaged into a single ﬁtness-defect
score for the strain. A signiﬁcance cut-off for each experiment was
determined by calculating the score cut-off required for a 0.05 FDR
[28,29].
Clustering analysis. Hierarchical clustering analysis was performed
with Cluster 3.0 (http://bonsai.ims.u-tokyo.ac.jp/;mdehoon/software/
cluster/software.htm) in Windows and Linux and visualized using Java
Treeview (http://jtreeview.sourceforge.net/) and slcview (http://
slcview.stanford.edu). Clustering along both experiment and gene
axes was performed on the calculated ﬁtness-defect scores (as
described above) using average linkage and Spearman’s rank
correlation as a distance metric (Dataset S5).
Conﬁrmations of individual strain growth rates. Individual yeast
strains were ﬁrst grown to saturation for approximately 20 h. Cells
were then diluted to an OD600 of 0.02 in a ﬁnal volume of 100 ll using
a Biomek FX Laboratory Automation Workstation (Beckman Coulter,
Allendale, New Jersey, United States). Normalized cultures were
grown in 96-well plates (Nunc, Rochester, New York, United States) in
Tecan GENios microplate readers (Tecan) for up to 30 h. The growth
rate of each culture was monitored by measuring the OD600 every 15
min and calculating the average doubling time (AvgG). AvgG was
calculated by recording the time (Dt) from the start of growth until
the optical density of the culture reached the calibrated ﬁve-
generation point (OD5g) and dividing this by the number of
generations, i.e., ﬁve. If the culture did not reach OD5g, AvgG was
calculated by using a binomial search to determine the fractional
generations of the optical density at the end of the growth (ODf),
assuming an exponential growth rate, then dividing the time to ODf
by the generations calculated.
We deﬁned the sensitivity to mechlorethamine of each individual
strain as the difference between the AvgG in mechlorethamine and in
DMSO (DAvgG ¼ AvgGmech   AvgGDMSO). Individual deletion strains
were scored as sensitive to mechlorethamine if this difference was
greater than that of wild-type þ/  the standard deviation calculated
from 18 wild-type replicates.
Viability assays. Selected strains were grown for ﬁve generations in
the presence of compound and cells collected. Cells were transferred
to 96-well plates and 5-fold dilutions were prepared. These dilutions
were then ‘‘stamped’’ onto YPD plates using a pintool calibrated to
deliver 5 ll. Cells were then allowed to form colonies for 2 d at 30 8C.
Supporting Information
The supporting ﬁles are also available in a searchable format at
http://chemogenomics.stanford.edu.
Dataset S1. Analyzed Microarray Data
Calculated ﬁtness-defect scores for each microarray experiment are
presented.
Found at DOI: 10.1371/journal.pgen.0010024.sd001 (7.2 KB XLS).
Dataset S2. Complete Set of Individual Strain Growth-Curve Data
Each strain has three growth curves corresponding to growth in 1%
DMSO, 31.3 lM mechlorethamine, and 62.5 lM mechlorethamine,
respectively.
Found at DOI: 10.1371/journal.pgen.0010024.sd002 (1.7 MB PNG).
Dataset S3. Unanalyzed, Raw Microarray Data from Affymetrix
Software, Part 1
This ﬁle contains 18 .cel ﬁles output from Affymetrix GeneChip
operating system; these ﬁles constitute half of the total microarray
dataset.
Found at DOI: 10.1371/journal.pgen.0010024.sd003 (9.2 MB ZIP).
Dataset S4. Unanalyzed, Raw Microarray Data from Affymetrix
Software, Part 2
This ﬁle contains 18 .cel ﬁles output from Affymetrix GeneChip
Operating System; these ﬁles constitute half of the total microarray
dataset.
Found at DOI: 10.1371/journal.pgen.0010024.sd004 (8.5 MB ZIP).
Dataset S5. Files Containing Cluster Output Used in Generating
Figure 4A
These text ﬁles can be opened by clustergram-viewing software to
browse the cluster shown in Figure 4A.
Found at DOI: 10.1371/journal.pgen.0010024.sd005 (24 KB TXT).
Protocol S1. Document Describing the Data Included in Dataset S1
Found at DOI: 10.1371/journal.pgen.0010024.sd006 (26 KB DOC).
Protocol S2. Document Describing the Data Included in Dataset S2
Found at DOI: 10.1371/journal.pgen.0010024.sd007 (24 KB DOC).
Protocol S3. Document Describing the Data Included in Datasets S3
and S4
Found at DOI: 10.1371/journal.pgen.0010024.sd008 (84 KB DOC).
Table S1. Strains Signiﬁcantly Sensitive in Two or More 20-
Generation Experiments that Exhibit Greater Sensitivity in Long-
Term Drug Exposure
Found at DOI: 10.1371/journal.pgen.0010024.st001 (61 KB DOC).
Table S2. Number of Times Strains Were Calculated as Signiﬁcantly
Sensitive for Each Drug Condition and Length of Drug Exposure
Found at DOI: 10.1371/journal.pgen.0010024.st002 (80 KB XLS).
Table S3. Individual Strains Used in this Study
Found at DOI: 10.1371/journal.pgen.0010024.st003 (39 KB DOC).
Accession Numbers
Swiss-Prot (http://www.ebi.ac.uk/swissprot) accession numbers for the
strains discussed in this paper are as follows: CSM2 (P40465), DDC1
(Q08949), ELG1 (Q12050), LTE1 (P07866), MAG1 (P22134), MEC3
(Q02574), MMS1 (Q06211), MMS4 (P38257), MPH1 (P40562), MRE11
(P32829), MUS81 (Q04149), PSO2 (P30620), PSY3 (Q12318), RAD1
(P06777), RAD2 (P07276), RAD4 (P14736), RAD5 (P32849), RAD6
(P06104), RAD9 (P14737), RAD10 (P06838), RAD14 (P28519), RAD17
(P48581), RAD18 (P10862), RAD24 (P32641), RAD50 (P12753), RAD51
(P25454), RAD52 (P06778), RAD54 (P32863), RAD55 (P38953), RAD57
(P25301), RAD59 (Q12223), REV1 (P12689), REV3 (P14284), REV7
(P38927), RMD7 (P40056), RTT101 (P47050), RTT107 (P38850), SHU1
(P38751), SHU2 (P38957), YDR291W (Q05549), YKL075C (P36083),
YLR426W (Q06417), YMR073C (Q04772), and XRS2 (P33301).
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